Author + information
- Received July 25, 2018
- Revision received August 17, 2018
- Accepted August 21, 2018
- Published online November 14, 2018.
- Andreas A. Kammerlander, MD, PhDa,
- Matthias Wiesinger, MDa,
- Franz Duca, MDa,
- Stefan Aschauer, MDa,
- Christina Binder, MDa,
- Caroline Zotter Tufaro, MSc, PhDa,
- Christian Nitsche, MDa,
- Roza Badre-Eslam, MDa,
- Robert Schönbauer, MDb,
- Philipp Bartko, MD, PhDa,
- Dietrich Beitzke, MDc,
- Christian Loewe, MDc,
- Christian Hengstenberg, MDa,
- Diana Bonderman, MDa and
- Julia Mascherbauer, MDa,∗ ()
- aDepartment of Internal Medicine II, Division of Cardiology, Medical University of Vienna, Vienna, Austria
- bDepartment of Cardiology, Wiener Neustadt Hospital, Wiener Neustadt, Austria
- cSection of Cardiovascular and Interventional Radiology, Department of Biomedical Imaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
- ↵∗Address for correspondence:
Dr. Julia Mascherbauer, Department of Cardiology, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria.
Objectives This study investigated the diagnostic and prognostic value of cardiac magnetic resonance (CMR) imaging in chronic aortic regurgitation (AR).
Background Accurate quantification of AR severity by echocardiography frequently remains difficult. CMR is recommended as the complementary method; however, its accuracy and prognostic utility remain unknown.
Methods A total of 232 consecutive patients (34.5% were females 55.5 ± 19.8 years of age) with chronic AR (including 40 with moderate to severe and 44 with severe AR on echocardiography) underwent CMR within 4 weeks of echocardiography. CMR included phase-contrast velocity-encoded imaging for the measurement of regurgitant volume and fraction at the sinotubular junction and assessment of holodiastolic retrograde flow (HRF) in the descending aorta. Significant AR was defined as the presence of HRF on CMR. Patients were followed prospectively, and multivariate Cox regression was applied for outcome analysis using a combination of heart failure, hospitalization, and cardiovascular death as primary endpoint.
Results AR severity on the basis of echo was reclassified in a significant number of patients according to CMR: 6.8% with mild AR on echo had HRF on CMR, whereas 34.1% with severe AR on echo did not have HRF on CMR and were reclassified as having nonsignificant AR. In 40 patients with uncertain AR severity (moderate to severe) on echo, 45.0% had HRF on CMR, indicating severe AR. Patients were followed for 35.3 ± 26.6 months. During that period, 63 patients (27.2%) reached the combined endpoint, including 43 (18.5%) with heart failure hospitalizations and 20 (8.6%) with cardiovascular deaths. By multivariate regression analysis, including clinical as well as imaging parameters, only N-terminal pro–B-type natriuretic peptide concentration (hazard ratio: 2.184 [95% confidence interval: 1.468 to 3.248]; p < 0.001) and HRF on CMR (hazard ratio: 2.774 [95% confidence interval: 1.131 to 6.802]; p = 0.026) remained significantly associated with outcome.
Conclusions In chronic AR, CMR has the potential to add important diagnostic and prognostic information.
Supported by Medical Scientific Fund of the Mayor of the City of Vienna grant 14078 (to Dr. Mascherbauer). All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
- Received July 25, 2018.
- Revision received August 17, 2018.
- Accepted August 21, 2018.
- 2018 American College of Cardiology Foundation
This article requires a subscription or purchase to view the full text. If you are a subscriber or member, click Login or the Subscribe link (top menu above) to access this article.